SecBot SecBot
8-K ·Filed Nov 5, 2026

NKTX

Nkarta, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed11d 8h ago SEC0001787400-26-000020
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The ACR Convergence 2026 presentations (Nov 8-11) are the primary near-term catalyst. Efficacy and safety data from the Ntrust trials in myositis and systemic sclerosis will determine whether NKX019's profile supports continued development and potential partnership interest. Monitor cash runway into 2029 provides no near-term financing urgency.

DirectionNeutral
Confidencehigh
Horizondays

Price Chart

Loading chart...

Executive Summary

Cash burn continued with cash and investments declining to $216.0 million from $243.2 million at Q2 end. The key catalyst is the upcoming presentation of initial clinical data for NKX019 in myositis and systemic sclerosis at ACR Convergence 2026 (November 8-11).

Key Financial Metrics

Revenue
$0.00
est $0.00

Key Facts

  • Cash, cash equivalents and investments of $216.0 million as of September 30, 2026, down from $243.2 million at June 30, 2026
  • R&D expenses were $29.5 million in Q3 2026, up from $20.2 million in Q3 2025
  • Initial clinical data for NKX019 in myositis and systemic sclerosis to be presented at ACR Convergence 2026 (Nov 8-11)
  • Cash expected to fund operations into 2029
  • Outpatient dosing underway at community-based sites

Financial Impact

Q3 2026 net loss of $33.3 million, cash burn of $27.2 million from Q2 to Q3

net losscash positionR&D expense

Risk Factors

  • Clinical-stage biotech with no approved products or revenue
  • Net loss widened year-over-year as R&D spending increased
  • Initial clinical data may not be predictive of future results
  • Competition from other cell therapies targeting autoimmune diseases

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001787400-26-000020
Document: nktx-20261105.htm0001787400-26-000020
Document: 0001787400-26-000020-index-headers.html0001787400-26-000020
Document: 0001787400-26-000020-index.html0001787400-26-000020
Document: 0001787400-26-000020.txt0001787400-26-000020
8-K Data (Synthetic)0001787400-26-000020

Track record

13 reports on NKTX

Performance horizon

5 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  2. Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  5. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
  6. Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
  7. May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
  8. Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
  9. Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
  10. Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026